PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDolutegravir
Tivicay(dolutegravir)
Dovato, Juluca, Tivicay, Triumeq (dolutegravir) is a small molecule pharmaceutical. Dolutegravir was first approved as Tivicay on 2013-08-12. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Tivicay (discontinued: Tivicay)
Combinations
Dovato, Juluca, Triumeq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dolutegravir sodium
Tradename
Company
Number
Date
Products
TIVICAY PDViiV HealthcareN-213983 RX2020-06-12
1 products, RLD, RS
TIVICAYViiV HealthcareN-204790 RX2013-08-12
1 products, RLD, RS
Show 1 discontinued
Abacavir sulfate
+
Dolutegravir sodium
+
Lamivudine
Tradename
Company
Number
Date
Products
TRIUMEQ PDViiV HealthcareN-215413 RX2022-03-30
1 products, RLD, RS
TRIUMEQViiV HealthcareN-205551 RX2014-08-22
1 products, RLD, RS
Dolutegravir sodium
+
Lamivudine
Tradename
Company
Number
Date
Products
DOVATOViiV HealthcareN-211994 RX2019-04-08
1 products, RLD, RS
Dolutegravir sodium
+
Rilpivirine hydrochloride
Tradename
Company
Number
Date
Products
JULUCAViiV HealthcareN-210192 RX2017-11-21
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dolutegravirExport only2021-03-05
dovatoNew Drug Application2024-04-18
julucaNew Drug Application2024-04-18
tivicayNew Drug Application2024-07-18
tivicay tivicay pdNew Drug Application2024-04-18
triumeqNew Drug Application2021-03-23
triumeq triumeq pdNew Drug Application2024-07-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
acquired immunodeficiency syndromeEFO_0000765D000163B20
hepatitis b—D006509—
Agency Specific
FDA
EMA
Expiration
Code
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE
2026-12-15PED
2026-06-15M-294
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE
2026-12-15PED
2026-06-15NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Dolutegravir Sodium / Rilpivirine Hydrochloride, Juluca, Viiv Hlthcare
104267802031-01-24DS, DPU-257
71258792025-04-21DS, DPU-257
Dolutegravir Sodium / Lamivudine, Dovato, Viiv Hlthcare
112349852031-01-24DPU-257
Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare
92429862029-12-08DS, DP
81293852027-10-05DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AJ: Integrase inhibitors, antiinfectives for systematic use
— J05AJ03: Dolutegravir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR13: Lamivudine, abacavir and dolutegravir
— J05AR21: Dolutegravir and rilpivirine
— J05AR25: Lamivudine and dolutegravir
— J05AR27: Lamivudine, tenofovir disoproxil and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
363 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B205450775148264
Acquired immunodeficiency syndromeD000163EFO_0000765B20321225141189
InfectionsD007239EFO_0000544—3211259881
HivD006678——9711251766
Communicable diseasesD003141——56165433
TuberculosisD014376EFO_0000774A15-A1981042121
Immunologic deficiency syndromesD007153HP_0002721D84.9—254—9
CoinfectionD060085———332—7
Drug interactionsD004347—————336
Cardiovascular diseasesD002318HP_0001626——1—214
Show 35 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.2—22—14
HepatitisD006505HP_0012115K75.9—22—14
Pulmonary tuberculosisD014397EFO_1000049A15131——4
Amyotrophic lateral sclerosisD000690HP_0007354G12.21112——4
Motor neuron diseaseD016472EFO_0003782G12.2112——4
SclerosisD012598——112——4
Hepatitis aD006506EFO_0007305B15—22——3
Hepatitis bD006509———12——2
Pregnancy rateD018873————2——2
PregnancyD011247EFO_0002950Z33.1121——2
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———161———17
Latent tuberculosisD055985—Z22.741———4
Treatment outcomeD016896———2———2
Disease progressionD018450———1——12
ViremiaD014766—B34.9—1———1
Respiratory tract infectionsD012141—J06.911———1
Htlv-ii infectionsD015491EFO_1001349——1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_0006344—1———12
Insulin resistanceD007333HP_0000855—1————1
Crush injuriesD000071576—T14.81————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autistic disorderD001321HP_0000717F84.0————55
Autism spectrum disorderD000067877HP_0000729F84.0————55
Metabolic syndromeD024821EFO_0000195E88.810————22
Contraception behaviorD003268——————11
Hiv-2D015498——————11
Persistent infectionD000088562——————11
EchocardiographyD004452——————11
Doppler echocardiographyD015150——————11
Transesophageal echocardiographyD017548——————11
Three-dimensional echocardiographyD019560——————11
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDolutegravir
INNdolutegravir
Description
Dolutegravir is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It is a monocarboxylic acid amide, an organic heterotricyclic compound, a secondary carboxamide and a difluorobenzene. It is a conjugate acid of a dolutegravir(1-).
Classification
Small molecule
Drug classantivirals: integrase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21
Identifiers
PDB—
CAS-ID1051375-16-6
RxCUI—
ChEMBL IDCHEMBL1229211
ChEBI ID76010
PubChem CID54726191
DrugBankDB08930
UNII IDDKO1W9H7M1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 21,152 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dovato, Triumeq, Triumeq triumeq pd
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
17,573 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use